Patient characteristics, n = 121
| Variable . | Analyzed cohort . | CoALL06-97 . | ||
|---|---|---|---|---|
| No. . | % . | No. . | % . | |
| Total no. | 121 | 572 | ||
| Age, y | ||||
| Median (range) | 4 (1-17) | |||
| Younger than 10 y | 100 | 83 | 460 | 80 |
| 10 y or older | 21 | 17 | 112 | 20 |
| WBC count at diagnosis, 50×103/μL | ||||
| Median (range) | 12.5 (0.5-263.7) | |||
| Less than 50 000/μL | 97 | 80 | 490 | 86 |
| 50 000/μL or more | 24 | 20 | 82 | 14 |
| Immunophenotype | ||||
| c-ALL | 81 | 67 | 415 | 73 |
| Pre-B-ALL | 32 | 26 | 134 | 23 |
| Pro-B-ALL | 8 | 7 | 23 | 4 |
| PVA score | ||||
| 3 to 4 | 27 | 22 | 150 | 26 |
| 5 to 7 | 63 | 52 | 252 | 44 |
| 8 to 9 | 6 | 5 | 28 | 5 |
| Unknown | 25 | 21 | 126 | 22 |
| Risk group* | ||||
| High risk (HR) | 57 | 47 | 250 | 43 |
| Low risk (LR) | 64 | 53 | 322 | 56 |
| Relapse | 19 | 16 | ||
| Death | 15 | 13 | ||
| DOD | 8 | 7 | ||
| Variable . | Analyzed cohort . | CoALL06-97 . | ||
|---|---|---|---|---|
| No. . | % . | No. . | % . | |
| Total no. | 121 | 572 | ||
| Age, y | ||||
| Median (range) | 4 (1-17) | |||
| Younger than 10 y | 100 | 83 | 460 | 80 |
| 10 y or older | 21 | 17 | 112 | 20 |
| WBC count at diagnosis, 50×103/μL | ||||
| Median (range) | 12.5 (0.5-263.7) | |||
| Less than 50 000/μL | 97 | 80 | 490 | 86 |
| 50 000/μL or more | 24 | 20 | 82 | 14 |
| Immunophenotype | ||||
| c-ALL | 81 | 67 | 415 | 73 |
| Pre-B-ALL | 32 | 26 | 134 | 23 |
| Pro-B-ALL | 8 | 7 | 23 | 4 |
| PVA score | ||||
| 3 to 4 | 27 | 22 | 150 | 26 |
| 5 to 7 | 63 | 52 | 252 | 44 |
| 8 to 9 | 6 | 5 | 28 | 5 |
| Unknown | 25 | 21 | 126 | 22 |
| Risk group* | ||||
| High risk (HR) | 57 | 47 | 250 | 43 |
| Low risk (LR) | 64 | 53 | 322 | 56 |
| Relapse | 19 | 16 | ||
| Death | 15 | 13 | ||
| DOD | 8 | 7 | ||
Patient characteristics of our prospectively analyzed cohort of precursor B-ALL patients are presented in comparison with the entire CoALL06-97 cohort.
In the CoALL06-97 study protocol, the criteria of therapy stratification for high-risk and low-risk patients at initial diagnosis include immunophenotype, leukocyte count (WBC), age, and the in vitro resistance to the chemotherapeutic agents prednisolone, vincristine, and asparaginase (PVA score).